卡铂与顺铂同步放化疗方案治疗局部晚期宫颈癌的疗效比较

Comparison of efficacy between concurrent chemoradiotherapy with carboplatin and cisplatin for treatment of locally advanced cervical cancer

目的比较卡铂与顺铂同步放化疗治疗局部晚期宫颈癌患者的临床效果。方法将99例局部晚期宫颈癌患者分为顺铂组48例与卡铂组51例,顺铂组采用顺铂同步放化疗,卡铂组采用卡铂同步放化疗,两组均采用同种放疗方式。比较两组患者同步放化疗的疗程数、肿瘤缓解率、生存率及毒性不良反应分级。结果两组患者肿瘤总体缓解率、各项毒性不良反应分级、3年无进展生存期及总生存期比较,差异均无统计学意义(P>0.05)。卡铂组接受≥4个化疗疗程的例数多于顺铂组(P<0.05)。结论局部晚期宫颈癌患者对卡铂的耐受性比对顺铂更好,而且卡铂方案不会降低患者的肿瘤缓解率和生存率。

Objective To compare the clinical efficacy between concurrent chemoradiotherapy with carboplatin and cisplatin for treating the patients with locally advanced cervical cancer. Methods A total of 99 patients with locally advanced cervical cancer were divided into cisplatin group（ n = 48 ） and carboplatin group （n = 51 ）. The cisplatin group received concurrent chemoradiotherapy with cisplatin while the carboplatin group received concurrent chemoradiotherapy with carboplatin. Both groups received the same radiotherapy. The course of concurrent chemoradiotherapy, tumor remission rate, survival rate and severity of toxic and adverse reactions were compared between the two groups. Results There were no significant differences in the overall remission rate, severity of any toxic and adverse reactions ,3-year progression-free survival or overall survival between the two groups （P 〉 0.05 ）. More cases receiving 4 or more than 4 courses of chemotherapy were observed in the carboplatin group compared to the cisplatin group （ P 〈 O. 05 ）. Conclusion For patients with locally advanced cervical cancer, carboplatin obtains better tolerance compared to cisplatin, and does not reduce the tumor remission rate and survival rate of the patients.